1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 15,300 | 15,500 | 16:38 | |
| 15,300 | 15,500 | 16:38 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 11.08. | Fortrea (FTRE) Gains Traction in Turnaround | 1 | Insider Monkey | ||
| 29.07. | Evercore ISI hebt Kursziel für Fortrea wegen Turnaround-Erfolgs auf 25 US-Dollar an | 4 | Investing.com Deutsch | ||
| 29.07. | Evercore ISI raises Fortrea stock price target to $25 on turnaround | 1 | Investing.com | ||
| FORTREA Aktie jetzt für 0€ handeln | |||||
| 29.07. | Fortrea Holdings beats top-line and bottom-line estimates; raises FY26 outlook | 3 | Seeking Alpha | ||
| 29.07. | Fortrea Holdings Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 29.07. | Fortrea Holdings Inc: Fortrea Reports Second Quarter 2026 Results | 611 | GlobeNewswire (Europe) | Four consecutive quarters of execution to drive commercial, operational and financial excellence Increases full-year guidance Highlights For the three months ended June 30, 2026: Revenues of $678.2... ► Artikel lesen | |
| 14.07. | Fortrea Holdings Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 26.06. | Fortrea Holdings Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 26.06. | Fortrea names Jason Knoblauch as CFO, reaffirms 2026 guidance | 1 | Investing.com | ||
| 26.06. | Fortrea names Jason Knoblauch as CFO | 3 | Seeking Alpha | ||
| 26.06. | Fortrea Reiterates FY26 Guidance, Targeting Revenues In Range Of $2.550B-$2.650B Vs $2.594B Est., And Adjusted EBITDA Of $190M-$220M | 1 | Benzinga.com | ||
| 26.06. | Fortrea Appoints Jason Knoblauch To Succeed Jill McConnell As CFO | 4 | RTTNews | ||
| 26.06. | Fortrea Holdings Inc: Fortrea Names Jason Knoblauch as Chief Financial Officer | 937 | GlobeNewswire (Europe) | DURHAM, N.C., June 26, 2026 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the "Company"), a leading global contract research organization (CRO), today announced that Jason Knoblauch has been appointed... ► Artikel lesen | |
| 12.06. | Fortrea Holdings Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 10.06. | Fortrea Holdings Inc: Fortrea Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) | 2 | GlobeNewswire (USA) | ||
| 11.05. | Mizuho raises Fortrea stock price target to $13 on EBITDA boost | 2 | Investing.com | ||
| 06.05. | BofA raises Fortrea stock price target on improved revenue trends | 4 | Investing.com | ||
| 05.05. | Fortrea reiterates 2026 revenue of $2.55B-$2.65B amid $190M-$220M adjusted EBITDA target | 2 | Seeking Alpha | ||
| 05.05. | Fortrea Holdings Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 05.05. | Evercore ISI raises Fortrea stock price target on execution improvements | 2 | Investing.com |
1 2 3 Weiter >>
48 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BB BIOTECH | 57,90 | +0,52 % | Edison Investment Research Limited: Edison issues report on BB Biotech (BION) | Edison Investment Research Limited
Edison issues report on BB Biotech (BION) 28-Jul-2026 / 14:20 GMT/BST
The issuer is solely responsible for the content of this announcement.
... ► Artikel lesen | |
| QIAGEN | 37,150 | +0,22 % | DAX Gewinner am Montag: Qiagen Aktie | Kursentwicklung und Chartanalyse | ||
| AMGEN | 366,50 | +1,19 % | Starkes Kernportfolio: Cantor Fitzgerald hebt Kursziel für Amgen Aktie an | ||
| NOVAVAX | 6,850 | -1,72 % | Novavax, Inc.: Novavax Reports Second Quarter 2026 Financial Results and Operational Highlights | Reported total revenue of $57 million for the second quarter of 2026 and raised full-year 2026 Revenue Framework
Improved GAAP Combined R&D and SG&A expense... ► Artikel lesen | |
| STRYKER | 288,60 | +0,73 % | Stryker-Aktie: Startet über 352,65 US$ die nächste Rally? | Die Stryker-Aktie hat sich nach dem scharfen Rücksetzer aus dem Frühjahr deutlich erholt und notiert inzwischen wieder bei 345,81 US$. Damit rückt der entscheidende Widerstandsbereich um 352,65 US$... ► Artikel lesen | |
| ILLUMINA | 163,26 | -2,12 % | ILLUMINA, INC. - 8-K, Current Report | ||
| CRISPR THERAPEUTICS | 45,215 | -3,58 % | CRISPR Therapeutics AG: CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2026 Financial Results | ZUG, Switzerland and BOSTON, Aug. 03, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today reported financial results for the second quarter ended June 30, 2026. "The second quarter reflected... ► Artikel lesen | |
| OCUGEN | 1,152 | -3,03 % | Ocugen präsentiert spätphasige Gentherapie-Strategie für Augenerkrankungen | ||
| INTELLIA THERAPEUTICS | 10,280 | -1,53 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates | Positive Phase 3 HAELO clinical data for lonvo-z in HAE presented at EAACI and published in New England Journal of MedicineAnticipate FDA acceptance of BLA for lonvo-z in second half of 2026 and U.S.... ► Artikel lesen | |
| TEMPUS AI | 43,305 | -2,86 % | Is Tempus AI Worth Buying as Growth Improves but Valuation Stays High? | ||
| SCORPIUS | - | - | Antares Global launches Scorpius MGA platform under Ian Morris | ||
| DEFENCE THERAPEUTICS | 0,331 | +1,53 % | Defence Therapeutics Inc.: Defence Therapeutics Strengthens Radiopharmaceutical Leadership with Appointment of Dr. Ryan Simms as Chief Operating Officer and Head of Radiopharmaceutical Programs | Montreal, Quebec--(Newsfile Corp. - August 17, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology company developing... ► Artikel lesen | |
| EDITAS MEDICINE | 2,480 | +1,22 % | Editas Medicine, Inc.: Editas Medicine Announces Second Quarter 2026 Results and Business Updates | EDIT-401 on track for CTN submission this month with data update in Q1 2027 Recently presented pre-clinical data demonstrating ~90% or greater mean reduction in multiple atherogenic lipoproteins,... ► Artikel lesen | |
| BIOCRYST PHARMACEUTICALS | 8,574 | -0,19 % | 'We're not afraid of competition': BioCryst CEO sets out strategy after scrapping internal discovery | ||
| KUROS BIOSCIENCES | 23,620 | +3,69 % | Kuros bestätigt nach starkem ersten Halbjahr Jahresziele | Zürich - Das Biotechunternehmen Kuros hat ein starkes erstes Halbjahr hinter sich. So wurde der Umsatz deutlich gesteigert und auch unter dem Strich steht nun ein Gewinn. Am Ausblick hält das Unternehmen... ► Artikel lesen |
Das Unternehmen FORTREA HOLDINGS INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 15,200 Euro und damit +4,11 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu FORTREA HOLDINGS INC finden Sie auf Wallstreet Online.